| Previous Close | 0.172 |
| Open | 0.174 |
| Bid | 0.000 x 0 |
| Ask | 0.000 x 0 |
| Day's Range | 0.171 - 0.177 |
| 52 Week Range | 0.160 - 0.980 |
| Volume | 995,407 |
| Avg. Volume | 1,890,303 |
| Market Cap | 50.78M |
| Beta | 1.12 |
| PE Ratio (TTM) | -0.31 |
| EPS (TTM) | -0.56 |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
- PR Newswire•4 days ago
NW BIO Announces Registered Direct Offering Of $1.75 Million
BETHESDA, Md., Sept. 20, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $1.75 million. In the transaction, the Company will sell approximately 8.75 million shares of common stock at a purchase price of $0.20 per share. Additionally, the investors will receive five year warrants to purchase up to approximately 4.375 million shares of common stock with an exercise price of $0.22 per share.
- Capital Cube•19 days ago
ETFs with exposure to Northwest Biotherapeutics, Inc. : September 6, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Northwest Biotherapeutics, Inc. Here are 5 ETFs with the largest exposure to NWBO-US. Comparing the performance and risk of Northwest Biotherapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- PR Newswire•23 days ago
DCVax® Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference
DCVax®-L Phase III GBM Trial & DCVax-Direct Phase I/II Updates; Overview Of A Broader Range Of DC Vax Public Data BETHESDA, Md. , Sept. 1, 2017 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW ...
